Combination of Whole-Body Baseline CT Radiomics and Clinical Parameters to Predict Response and Survival in a Stage-IV Melanoma Cohort Undergoing Immunotherapy.
Felix PeisenAnnika HänschAlessa HeringAndreas Stefan BrendlinSaif AfatKonstantin NikolaouSergios GatidisThomas Kurt EigentlerTeresa AmaralJan H MoltzAhmed E OthmanPublished in: Cancers (2022)
The study indicated a potential, but non-significant, added value of radiomics for six-month and twelve-month survival prediction of stage-IV melanoma patients undergoing immunotherapy.